Takeda Pharmaceutical (TAK) EBT Margin Growth (3y) (2020 - 2026)
Powered by 
Analysis
Takeda Pharmaceutical (TAK) EBT Margin Growth (3y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | -265.00 |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 636.00 |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 3,137.00 |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 625.00 |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -2,179.00 |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -977.00 |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 1,581.00 |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | -861.00 |
| 10 | Takeda Pharmaceutical | 2.61 Bn | -3.19 Bn | 5.10 Bn | 58.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 58.00 |
| Mar 31, 2026 | -135.00 |
| Dec 31, 2025 | -5,134.00 |
| Sep 30, 2025 | 242.00 |
| Jun 30, 2025 | -238.00 |
| Mar 31, 2025 | -1,046.00 |
| Dec 31, 2024 | -1,820.00 |
| Sep 30, 2024 | 73.00 |
| Jun 30, 2024 | -1,217.00 |
| Mar 31, 2024 | -1,764.00 |
| Dec 31, 2023 | -856.00 |
| Sep 30, 2023 | 1,078.00 |
| Jun 30, 2023 | -349.00 |
| Mar 31, 2023 | -1,514.00 |
| Sep 30, 2022 | 384.00 |
| Jun 30, 2022 | 1,480.00 |
| Mar 31, 2022 | -361.00 |
| Dec 31, 2021 | -152.00 |
| Sep 30, 2021 | -826.00 |
| Jun 30, 2021 | 262.00 |